Leukemia falls into four main types, divided by how fast the cancer grows (acute or chronic) and which blood cell line it starts in (lymphoid or myeloid). Those four types are acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML). An estimated 67,790 new cases will be diagnosed in the United States in 2026, with AML and CLL being the most common forms in adults.
Understanding which type someone has matters because each behaves differently, affects different age groups, progresses at a different speed, and responds to different treatments.
How Leukemia Types Are Classified
All leukemia starts in the bone marrow, where blood cells are made. The classification comes down to two questions: which cell became cancerous, and how quickly.
Lymphoid vs. myeloid refers to the type of white blood cell involved. Lymphoid stem cells normally mature into lymphocytes, the immune cells that produce antibodies (B cells) and directly attack infections (T cells). Myeloid stem cells normally develop into a broader range of cells: white blood cells like granulocytes and monocytes that fight bacteria and fungi, plus red blood cells that carry oxygen and platelets that help blood clot. When either cell line turns cancerous, the bone marrow floods the bloodstream with defective cells that crowd out healthy ones.
Acute vs. chronic describes the speed. Acute leukemias involve immature cells (blasts) that multiply rapidly and cause symptoms within days or weeks. Chronic leukemias involve more mature cells that accumulate slowly, sometimes over years, and may cause no symptoms at all in the early stages.
Acute Lymphoblastic Leukemia (ALL)
ALL is the most common leukemia in children, peaking between ages 2 and 5. It can also occur in adults, though far less frequently. The cancer begins in immature lymphoid cells that multiply uncontrollably instead of maturing into functional lymphocytes.
Because the disease moves fast, symptoms tend to appear suddenly. Common signs include unusual fatigue, frequent infections, easy bruising, nosebleeds, joint pain, swollen lymph nodes, night sweats, and tiny red spots on the skin called petechiae (caused by very low platelet counts). Pallor and shortness of breath reflect the drop in healthy red blood cells.
The overall five-year survival rate for ALL is 72%, but that number hides a dramatic age gap. Children survive at rates around 90%, thanks in part to how well pediatric ALL responds to treatment. For adults, the five-year survival rate drops to roughly 30% to 40%.
Acute Myeloid Leukemia (AML)
AML is one of the most common leukemias in adults and one of the most aggressive. It starts in myeloid cells, the precursors to infection-fighting white blood cells, red blood cells, and platelets. Instead of maturing, these cells stall as blasts and pile up in the bone marrow, eventually spilling into the bloodstream.
Symptoms overlap with ALL: fatigue, infections, bruising, and bleeding. Because myeloid cells are responsible for a wider range of blood cell production, AML can simultaneously lower red blood cells, platelets, and functional white blood cells, creating a combination of anemia, bleeding problems, and vulnerability to infection that escalates quickly.
AML is increasingly classified by the specific genetic mutations driving each case. Mutations in genes like FLT3, RUNX1, and CEBPA help oncologists predict how the leukemia will behave and choose targeted treatments. This is a shift from older classification systems that grouped AML primarily by how cells looked under a microscope.
Chronic Lymphocytic Leukemia (CLL)
CLL is the most common chronic leukemia in adults. It involves mature-looking but dysfunctional B lymphocytes that accumulate slowly in the blood, bone marrow, and lymph nodes. Many people are diagnosed after a routine blood test reveals an abnormally high white blood cell count, with no symptoms at all.
When symptoms do develop, they tend to be subtle at first: gradual fatigue, enlarged lymph nodes, recurrent infections, or unintentional weight loss. The disease progresses at wildly different rates from person to person. Some patients live decades without needing treatment. Others progress more quickly and require intervention within a few years of diagnosis.
Doctors stage CLL using systems that track how far the disease has spread and whether it has started to affect normal blood cell production. Early-stage CLL (low risk) involves elevated lymphocyte counts but normal red blood cells and platelets and limited lymph node involvement. Intermediate stages show expanding lymph node areas or an enlarged spleen. High-risk stages are marked by anemia or low platelet counts, signs that the leukemia is crowding out normal bone marrow function. Staging helps determine whether someone needs treatment right away or can be safely monitored with regular blood work, an approach called “watch and wait.”
Chronic Myeloid Leukemia (CML)
CML has a unique genetic signature. Nearly all cases are driven by the Philadelphia chromosome, an abnormality created when pieces of chromosomes 9 and 22 swap places. This swap produces a fused gene called BCR-ABL, which makes a protein that constantly signals myeloid cells to grow and divide. The result is a steady overproduction of white blood cells.
CML moves through three distinct phases. The chronic phase is the earliest and most stable, often lasting years. Many people feel fine during this stage or notice only mild fatigue and fullness in the upper left abdomen from an enlarged spleen. The accelerated phase signals that the disease is becoming harder to control, with rising blast counts and worsening symptoms. Blast crisis is the most advanced phase, where CML behaves more like an acute leukemia, with large numbers of immature cells flooding the bone marrow and blood.
The development of drugs that specifically block the BCR-ABL protein transformed CML from a near-certain death sentence into a manageable chronic condition for most patients. The first of these targeted therapies became the standard treatment for chronic-phase CML and remains the foundation of care, with newer versions available when the original stops working.
Rare Leukemia Variants
Beyond the four major types, several rare forms exist. Hairy cell leukemia is one of the better known, accounting for just 1% to 2% of all adult leukemia cases, with about 600 to 800 new diagnoses per year in the U.S. It gets its name from the fine, hair-like projections visible on the surface of the cancerous B lymphocytes under a microscope.
Hairy cell leukemia affects men about four times more often than women, with most cases occurring in men over age 50. The abnormal cells accumulate in the bone marrow and spleen, leading to a shortage of normal blood cells. Typical symptoms include fatigue, weakness, easy bruising, frequent infections, and abdominal discomfort from an enlarged spleen. Despite its rarity, hairy cell leukemia generally responds very well to treatment, and most patients achieve long-lasting remissions.
Other rare variants include T-cell prolymphocytic leukemia, juvenile myelomonocytic leukemia (which affects young children), and leukemias of ambiguous lineage, where the cancer cells show features of both lymphoid and myeloid lines, making classification difficult.
How Leukemia Types Are Diagnosed
Identifying the specific type of leukemia requires more than a standard blood test. A complete blood count is usually the first clue, revealing abnormal numbers of white blood cells, low red blood cells, or low platelets. But pinpointing the exact type involves several additional steps.
A bone marrow biopsy provides a direct sample of the tissue where leukemia originates. Pathologists examine it for the percentage of blast cells and the overall health of blood cell production. Flow cytometry, a laser-based lab technique, passes individual cells through a beam of light and reads the protein markers on their surface. Healthy cells carry a predictable pattern of surface markers that match their type and maturity level. Leukemia cells show abnormal patterns, and the specific pattern helps distinguish ALL from AML from CLL and other types.
Genetic testing rounds out the picture. Techniques like cytogenetic analysis and molecular profiling identify chromosome abnormalities (such as the Philadelphia chromosome in CML) and specific gene mutations. These results increasingly guide treatment decisions, since two patients with the same broad type of leukemia may have very different outcomes depending on which mutations are driving their disease.